SLXN
Silexion Therapeutics Ltd. NASDAQ Listed Aug 16, 2024$2.59
+1.57%
vs $2.55
Mkt Cap $3.4M
52w Low $0.27
15.8% of range
52w High $14.94
50d MA $2.23
200d MA $2.34
P/E (TTM)
0.1x
EV/EBITDA
—
P/B
1.3x
Debt/Equity
0.2x
ROE
-457.6%
P/FCF
-0.3x
RSI (14)
30.30
ATR (14)
$0.30
Beta
0.06
50d MA
$2.23
200d MA
$2.34
Avg Volume
11.4M
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
The Goldyne Savad Institute of Gene Therapy · Jerusalem, L3 9112001 · IL
Data updated apr 27, 2026 1:49am
· Source: financialmodelingprep.com